EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oligoprogression During First-Line Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Comparative Outcomes of Metastasis-Directed Radiotherapy and Systemic Treatment Change

Murat Günaltılı iD, Murad Guliyev iD, Zeliha Birsin iD, Emir Çerme, Vali Aliyev, Hamza Abbasov iD, Selin Cebeci iD, Seda Jeral iD, Ebru Çiçek, Süheyla Atak, Halil Cumhur Yıldırım, Nebi Serkan Demirci und 2 weitere

Journal of Clinical Medicine · 17.04.2026 · 15 (8) · 3067

DOI: 10.3390/jcm15083067 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 17.04.2026. Verfasst von Murat Günaltılı und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Turkey. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: We evaluated the clinical outcomes of two commonly used approaches for managing oligoprogression arising during first-line therapy for metastatic hormone-sensitive prostate cancer (mHSPC): metastasis-directed radiotherapy (RT) with continuation of the ongoing systemic regimen and immediate transition to another systemic treatment.

Methods

A total of 81 patients with mHSPC who experienced radiologically confirmed oligoprogression during first-line systemic therapy were retrospectively evaluated. Oligoprogression was defined as progression involving three or fewer metastatic sites. Patients were categorized into an RT group (metastasis-directed RT with continuation of the same regimen) or a treatment-change group (immediate switch in systemic therapy without RT). Post-oligoprogression radiologic progression-free survival (rPFS) and overall survival (OS) were evaluated using Kaplan–Meier estimates and Cox proportional hazards models.

Results

Thirty-one patients received metastasis-directed RT, whereas fifty underwent a change in systemic therapy. The median post-oligoprogression rPFS was 25.8 months (95% CI, 16.3–35.2) in the entire cohort and did not differ significantly between the treatment-change (26.8 months) and RT groups (22.7 months; p = 0.828). The median OS was 42.6 months overall, with comparable outcomes between the treatment-change (42.6 months) and RT groups (52.4 months; p = 0.452).

Conclusions

In patients with mHSPC who developed oligoprogression during first-line systemic therapy, metastasis-directed RT with continuation of the same regimen and immediate change in systemic treatment were associated with comparable post-oligoprogression outcomes in our cohort. These findings suggest that both strategies may be feasible in selected patients. Prospective studies may help clarify which patients are more likely to benefit from each strategy.

Schlagwörter

Stichwörter der Autor:innen

metastasis-directed radiotherapymetastatic hormone-sensitive prostate canceroligoprogressionprostate cancerradiologic progression-free survival

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Turkey.
  • Department of Radiation Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Turkey.

ORCID-Profile: Murat Günaltılı, Murad Guliyev, Zeliha Birsin, Hamza Abbasov, Selin Cebeci, Seda Jeral, Fazilet Öner Dinçbaş, Özkan Alan

Zitieren

APA

Günaltılı, M., Guliyev, M., Birsin, Z., Çerme, E., Aliyev, V., Abbasov, H., Cebeci, S., Jeral, S., Çiçek, E., Atak, S., Yıldırım, H. C., Demirci, N. S., Dinçbaş, F. Ö., & Alan, Ö. (2026). Oligoprogression During First-Line Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Comparative Outcomes of Metastasis-Directed Radiotherapy and Systemic Treatment Change. Journal of Clinical Medicine, 15(8), 3067. https://doi.org/10.3390/jcm15083067

Vancouver

Günaltılı M, Guliyev M, Birsin Z, Çerme E, Aliyev V, Abbasov H, et al. Oligoprogression During First-Line Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Comparative Outcomes of Metastasis-Directed Radiotherapy and Systemic Treatment Change. Journal of Clinical Medicine. 2026;15(8):3067. doi:10.3390/jcm15083067

BibTeX
@article{Gnaltl2026,
  author = {Günaltılı, Murat and Guliyev, Murad and Birsin, Zeliha and Çerme, Emir and Aliyev, Vali and Abbasov, Hamza and Cebeci, Selin and Jeral, Seda and Çiçek, Ebru and Atak, Süheyla and Yıldırım, Halil Cumhur and Demirci, Nebi Serkan and Dinçbaş, Fazilet Öner and Alan, Özkan},
  title = {Oligoprogression During First-Line Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Comparative Outcomes of Metastasis-Directed Radiotherapy and Systemic Treatment Change},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {8},
  pages = {3067},
  doi = {10.3390/jcm15083067}
}
Kostenlos starten →